RxDoctor Payments Data

Faiza Malik, MD

Family Medicine · Webster, TXNPI 1497061303

Payments from drug & device makers

$1,131in general payments, 2019–2025

Across 55 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$147
  • Lilly USA, LLC$133
  • Pfizer$132
  • Novo Nordisk$122
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
  • Abbott$91
  • plus $414 from 13 others

What the payments were for

  • Food & beverage$1,131100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,131 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,554
Medicare patients
199
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$50,227
EliquisApixaban30$32,219
JardianceEmpagliflozin30$26,129
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,138
Atorvastatin Calcium140$1,512
Clonidine13$1,275
Metoprolol Succinate43$661
Rosuvastatin Calcium35$644
Albuterol Sulfate HfaAlbuterol Sulfate27$606
Levothyroxine Sodium59$601
Losartan Potassium48$475
Pantoprazole Sodium48$454
ClopidogrelClopidogrel Bisulfate39$311
Tamsulosin Hcl20$301
Gabapentin37$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$133$50,22744 claims
PfizerEliquis$132$32,21930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →